Business
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
DUBLIN, May 07, 2026--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/46d8dbb3b6513e452769726778a0a1cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RIVmZPwvSWdi.jKOMPoO.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwOA--/https://media.zenfs.com/en/business-wire.com/46d8dbb3b6513e452769726778a0a1cb","width":960,"height":308},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jDpU.GI1xMvvF5lgIkMYzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwNg--/https://media.zenfs.com/en/business-wire.com/46d8dbb3b6513e452769726778a0a1cb","width":640,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8mtxvXtLWYMFE8Ea31QbgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA-/https://media.zenfs.com/en/business-wire.com/46d8dbb3b6513e452769726778a0a1cb","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million","length":169,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash","length":275,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment","length":232,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026)","length":251,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Sq...